Swiss Life Asset Management’s AstraZeneca AZN Stock Holding History

Swiss Life Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,490	Closed	-$290K	–	569
2021 Q4	$290K	Hold	2,490	–	–	﹤0.01%	535
2021 Q3	$299K	Buy	+2,490	New	+$290K	﹤0.01%	531

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Swiss Life Asset Management's AZN Position: Q1 2022 in Review

Swiss Life Asset Management sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 2,490 shares — an estimated $290K sold.

Swiss Life Asset Management first reported a position in AZN in Q3 2021 and held it in 2 quarters. The position peaked at $299K in Q3 2021. 981 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

Swiss Life Asset Management reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
Swiss Life Asset Management sold 2,490 AstraZeneca shares in Q1 2022, an estimated $290K.
Swiss Life Asset Management first reported a position in AstraZeneca in Q3 2021 and held it in 2 quarters.
Swiss Life Asset Management's AstraZeneca position peaked at $299K in Q3 2021.
981 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Swiss Life Asset Management's 13F filing for Q1 2022, filed 9 Dec 2025.